INTRODUCTION AND OBJECTIVES:
Evidence for best practice follow up of node positive SCC of the penis (SCCp) is scant. Our practice mirrors EAU guidelines; 3 monthly review CT (TAP) for 2 years and 6 monthly for years 3-5 (min. 16 scans). We aim to determine optimum frequency and duration of CT TAP and length of follow up based on site and timing of first regional or distant recurrence.
METHODS: A prospective database of all penile cancer patients treated at our centre from 2002-2017 was reviewed. We identified newly diagnosed pathologically node positive patients who were disease free on surveillance. Parameters assessed were nodal pathological stage, site and time of first recurrence. All pathology was rereviewed and reclassified using TNM 7. Surveillance time was defined from whichever time was latest of inguinal or pelvic node surgery (completion of surgery).
RESULTS: Of 1019 patients with a new diagnosis of SCCp, 224 patients were node positive, on surveillance and met our inclusion criteria with full follow up data; pN1 (48), pN2 (33) and pN3 (143).
Of the pN1 patients, 6 had recurrence, (range 1-11 months). 10 pN2 patients had recurrence (range 0 e 12 months). Of the pN3 group, 84 patients had disease recurrence (66 in year 1, 14 in year 2, 2 in years 3-5). Site of first recurrence was groin 21%, pelvis 28%, chest 31%, 20% involving the retroperitoneum, kidney and bones.
CONCLUSIONS: Regional and distant recurrence was not observed in pN1 and pN2 patients after 12 months surveillance. For pN3 patients, 97% did not relapse after 24 months. We confirmed that the sites of progression supports CT TAP as the imaging modality of choice. We propose a new CT TAP surveillance protocol of 2 years for pN1 and pN2 patients with 3 monthly scans for the first year and 6 monthly for the second and a further year for pN3. Patients could then be safely discharged.
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Madeleine L. Burg*, Laya Jacob, Saum Ghodoussipour, Shane M. Pearce, Sumeet Bhanvadia, Hooman Djaladat, Anne K. Schuckman, Siamak Daneshmand, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Midline extraperitoneal retroperitoneal lymph node dissection (EP-RPLND) for testicular germ cell tumors (GCT) has been shown to have significantly decreased morbidity compared to a transperitoneal approach. We aimed to review patients who underwent EP-RPLND for surgical outcomes.
METHODS: Using an IRB approved TGCT database, all patients who underwent either primary or post-chemotherapy EP-RPLND from 2010-2017 were reviewed. Surgical variables recorded include estimated blood loss (EBL) and intraoperative blood transfusions, if nerve-sparing and other intraabdominal procedures performed, largest preoperative lymph node/mass size (per imaging), lymph node yield, length of hospital stay (LOS), postoperative ejaculatory function, and 90-day complications per Clavien-Dindo classification system (CD).
RESULTS: Out of 131 EP-RPLND performed, 105 were consented for TGCT database. 3 patients who underwent desperation EP-RPLND were excluded, resulting in 102 patients. 30 patients underwent primary EP-RPLND (6 CS I, 19 CS IIA, 4 CS IIB, 1 CS IIC). 72 patients underwent EP-PC-RPLND. Surgical outcomes listed in Table 1 . Median LOS was 3 days (IQR 2-3). 83 patients (81%) underwent nerve-sparing procedure. 66 patients (65%) had Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e711
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